Troy Edward Wilson Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson sold 27,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $3.33, for a total value of $89,910.00. Following the sale, the director now owns 350 shares in the company, valued at approximately $1,165.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $3.09 on Thursday. Puma Biotechnology, Inc. has a twelve month low of $2.13 and a twelve month high of $7.73. The stock has a market capitalization of $149.06 million, a P/E ratio of 9.36 and a beta of 1.04. The company has a current ratio of 1.46, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. The business’s fifty day moving average price is $4.36 and its 200 day moving average price is $4.85.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.12. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The firm had revenue of $43.80 million for the quarter, compared to analysts’ expectations of $41.53 million. As a group, research analysts anticipate that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Great Point Partners LLC acquired a new position in Puma Biotechnology in the fourth quarter valued at $4,734,000. Jump Financial LLC raised its position in Puma Biotechnology by 131.7% in the fourth quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 32,510 shares during the period. Citigroup Inc. purchased a new position in Puma Biotechnology in the third quarter valued at about $262,000. Assenagon Asset Management S.A. raised its position in Puma Biotechnology by 23.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 15,897 shares during the period. Finally, Ritholtz Wealth Management purchased a new position in Puma Biotechnology in the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

PBYI has been the topic of several analyst reports. StockNews.com upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, June 12th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Monday, June 3rd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.